| Literature DB >> 31160364 |
Yuri Kim1,2, Eri Allen1, Lillia A Baird1, Elise M Symer1, Filiz T Korkmaz1, Elim Na1,3, Christine V Odom1,4, Matthew R Jones1,3, Joseph P Mizgerd1,3,4,5, Katrina E Traber1,3, Lee J Quinton6,2,3.
Abstract
Pneumonia and sepsis are distinct but integrally linked public health concerns. The hepatic acute-phase response (APR), which is largely dependent on transcription factors NF-κB RelA and STAT3, is a hallmark of these pathologies and other injurious conditions. Inactivation of the APR can promote liver injury, a frequently observed organ dysfunction during sepsis. However, whether or how the acute-phase changes promote liver tissue resilience during infections is unclear. To determine the hepatoprotective role of the hepatic APR, we utilized mice bearing hepatocyte-specific deletions of either RelA or STAT3. Mice were challenged intratracheally (i.t.), intravenously (i.v.), or intraperitoneally (i.p.) with Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, lipopolysaccharide (LPS), or alpha-galactosylceramide (αGalCer) to induce pneumonia, sepsis, or NKT cell activation. Liver injury was observed in RelA-null (hepRelAΔ/Δ) mice but not STAT3-null (hepSTAT3Δ/Δ) mice during pneumonia. The absence of RelA resulted in hepatotoxicity across several models of pneumonia, sepsis, and NKT cell activation. Injury was associated with increased levels of activated caspase-3 and -8 and substantial alteration of the hepatic transcriptome. Hepatotoxicity in the absence of RelA could be reversed by neutralization of tumor necrosis factor alpha (TNF-α). These results indicate the requirement of RelA-dependent inducible hepatoprotection during pneumonia and sepsis. Further, the results demonstrate that RelA-dependent gene programs are critical for maintaining liver homeostasis against TNF-α-driven immunotoxicity.Entities:
Keywords: acute-phase response; inflammation; liver; pneumonia; sepsis
Mesh:
Substances:
Year: 2019 PMID: 31160364 PMCID: PMC6652780 DOI: 10.1128/IAI.00132-19
Source DB: PubMed Journal: Infect Immun ISSN: 0019-9567 Impact factor: 3.441